Home Immunology & Inflammation Immunology & Inflammation related chemical 5-Acetylsalicylic acid

research use only

5-Acetylsalicylic acid Immunology & Inflammation related chemical

Cat.No.S4789

5-Acetylsalicylic acid (5-acetyl-2-hydroxybenzoic acid) is a nonsteroidal anti-inflammatory drug.
5-Acetylsalicylic acid Immunology & Inflammation related chemical Chemical Structure

Chemical Structure

Molecular Weight: 180.16

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S478901 DMSO]36 mg/mL]false]]]false]]]false Purity: 99.88%
99.88

Chemical Information, Storage & Stability

Molecular Weight 180.16 Formula

C9H8O4

 Storage (From the date of receipt)
CAS No. 13110-96-8 Download SDF Storage of Stock Solutions

Synonyms 5-acetyl-2-hydroxybenzoic acid Smiles CC(=O)C1=CC(=C(C=C1)O)C(=O)O

Solubility

In vitro
Batch:

DMSO : 36 mg/mL ( (199.82 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro
5-Acetylsalicylic acid (5-ASA) is initially shown to downregulate the inducible cyclooxygenase/prostaglandin E2 (COX-2/PGE2) signalling in mucosa inflammatory cells. Generally 5-ASA decreases the nuclear factor κB (NF-κB) activity induced by TNF-α, modulating the NF-κB inhibitor, IκBα, as well as the NF-κB transcriptional activity induced by IL-1, although it does prevent neither IL-1-induced IκBα degradation nor IL-1-induced nuclear translocation of NF-κB family members. 5-ASA is also found to increase β-catenin expression/phosphorylation and the expression of μ-protocadherin in intestine cells while reducing the expression of Wnt/β-catenin target genes and the activity of the protein phosphatase 2A. 5-ASA enhances PPAR-γ expression/activity in intestine cells and promotes its translocation from the cytoplasm to the nucleus -- this is followed by the induction of the tumour suppressor gene PTEN, the activation of caspases 8 and 3, and the inhibition of antiapoptotic proteins. It induces membranous expression of E-cadherin and increases cell adhesion through inhibition of p-21 activated kinase-1 and modulation of N-glycosylation; Also interferes with the mitogen activated protein kinase and phosphatidylinositol-4,5-bisphosphate 3-kinase/Akt pathways[1].
In vivo
5-ASA is rapidly adsorbed and extensively acetylated to N-acetyl-5-ASA by the N-acetyltransferase 1 enzyme in intestinal epithelial cells and the liver. It is generally well tolerated and the most common side effects include headache, nausea, and abdominal pain[1].
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02246686 Terminated
Colitis Ulcerative
Bayer
 November 2014 Phase 2
NCT02125292 Completed
Healthy
Shire|Takeda
 June 2 2014 Phase 1
NCT02077777 Completed
Colorectal Cancer
SOFAR S.p.A.
 October 2012 Phase 2
NCT01678300 Completed
Ulcerative Colitis
Beth Israel Deaconess Medical Center
 August 2012 --

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.